02606nas a2200265   4500008004100000022001400041245016900055210006900224260000800293300001100301490000700312520164400319653000601963653002601969653001801995653003102013653002802044100002502072700002802097700002202125700002202147700001902169700002302188856012902211       2022                        eng d  a1018-364700a2,4-Di-tert-butylphenol (2,4-DTBP) purified from streptomyces sp. KCA1 from phyllanthus niruri: isolation, characterization, antibacterial and anticancer properties0 a24Ditertbutylphenol 24DTBP purified from streptomyces sp KCA1 fr  cJUL  a1020880 v343 a<p>
	Objectives: The present study reports the bioactivity of 2,4-Di-tert-butylphenol (2,4-DTBP) purified from an endophytic Streptomyces species KCA1 isolated from the leaves of Phyllanthus niruri and its antibacterial and anticancer properties. Methods: The extracellular metabolites were produced from the strain KCA1 by submerged fermentation using ethyl acetate. The crude extract was further evaluated for antibacterial activity against set of pathogens. Active metabolite from the extract was purified using chromatography techniques and detected its antibacterial activity by disc diffusion assay. The molecular structure of the active molecule was identified through various spectral study. Moreover, the bioactive metabolite 2,4-DTBP was analyzed antibacterial and anti-proliferative activity. Results: Strain KCA1 was identified as Streptomyces sp. In the preliminary screening, the crude extract exhibited broad spectrum activity against various bacterial pathogens. Based on the spectral properties, the active metabolite was identified as 2,4-Di-tert-butylphenol. The MIC of active compound 2,4-DTBP inhibited E. coli ATCC 25922 and S. aureus ATCC 29213 at 50 lg/ml and 0.78 lg/ml, respectively. The IC50 value of 2,4-DTBP was found to be 11.0 lg/ml and 116.8 lg/ml, against breast cancer cell line (MCF7) and normal VERO cell line, respectively. Conclusions: This study concluded that 2,4-DTBP, produced from the endophytic Streptomyces sp. KCA1, is the potential candidate to develop as promising antibacterial and anticancer agent. (C) 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University.</p>
10a210a4-Di-tert-butylphenol10aAntibacterial10aantiproliferative activity10aEndophytic Streptomyces1 aSeenivasan, Ayswarya1 aManikkam, Radhakrishnan1 aKaari, Manigundan1 aSahu, Amit, Kumar1 aSaid, Madhukar1 aDastager, Syed, G.  uhttps://library.ncl.res.in/content/24-di-tert-butylphenol-24-dtbp-purified-streptomyces-sp-kca1-phyllanthus-niruri-isolation02704nas a2200337   4500008004100000022001400041245014400055210006900199260000800268300001400276490000800290520156600298653000601864653002601870653001601896653002001912653002201932653002801954100002201982700002002004700002802024700002902052700002202081700002502103700002202128700002202150700001902172700002302191700002902214856012302243       2023                        eng d  a0273-228900aNovel finding: 2,4-Di-tert-butylphenol from streptomyces bacillaris ANS2 effective against mycobacterium tuberculosis and cancer cell lines0 aNovel finding 24Ditertbutylphenol from streptomyces bacillaris A  cNOV  a6572-65850 v1953 a<p>
	The aim of the present study is to identify actinobacteria Streptomyces bacillaris ANS2 as the source of the potentially beneficial compound 2,4-di-tert-butylphenol, describe its chemical components, and assess its anti-tubercular (TB) and anti-cancer properties. Ethyl acetate was used in the agar surface fermentation of S. bacillaris ANS2 to produce the bioactive metabolites. Using various chromatographic and spectroscopy analyses, the potential bioactive metabolite separated and identified as 2,4-di-tert-butylphenol (2,4-DTBP). The lead compound 2,4-DTBP inhibited 78% and 74% of relative light unit (RLU) decrease against MDR Mycobacterium tuberculosis at 100ug/ml and 50ug/ml concentrations, respectively. The Wayne model was used to assess the latent/dormant potential in M. tuberculosis H37RV at various doses, and the MIC for the isolated molecule was found to be 100ug/ml. Furthermore, the molecular docking of 2,4-DTBP was docked using Autodock Vinasuite onto the substrate binding site of the target Mycobacterium lysine aminotransferase (LAT) and the grid box was configured for the docking run to cover the whole LAT dimer interface. At a dosage of 1 mg/ml, the anti-cancer activity of the compound 2,4-DTBP was 88% and 89% inhibited against the HT 29 (colon cancer) and HeLa (cervical cancer) cell lines. According to our literature survey, this present finding may be the first report on anti-TB activity of 2,4-DTBP and has the potential to become an effective natural source and the promising pharmaceutical drug in the future.</p>
10a210a4-Di-tert-butylphenol10aanti-cancer10aAnti-tubercular10aMolecular docking10aStreptomyces bacillaris1 aKaari, Manigundan1 aJoseph, Jerrine1 aManikkam, Radhakrishnan1 aKalyanasundaram, Revathy1 aSivaraj, Anbarasu1 aAnbalmani, Sivarajan1 aMurthy, Sangeetha1 aSahu, Amit, Kumar1 aSaid, Madhukar1 aDastager, Syed, G.1 aRamasamy, Balagurunathan  uhttps://library.ncl.res.in/content/novel-finding-24-di-tert-butylphenol-streptomyces-bacillaris-ans2-effective-against